Subtype
Prostate Carcinoma
CI-CAN-00006533Explore in graph →
429 active trials16 approved drugs20 evidence items
Loading cancer entity…
Subtype
CI-CAN-00006533Explore in graph →
Clinical trials
1,176 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (184)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00684970 | Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)(TLH-202) | unknown | Phase 2 | 100 | Tiltan Pharma Ltd.INDUSTRY | 1 | Dec 5, 2013 | clinicaltrials |
| NCT01938339 | Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer | unknown | N/A | 60 | Seoul National University HospitalOTHER | 1 | Dec 5, 2013 | clinicaltrials |
| NCT00181597 | Trilostane for Androgen-Independent Prostate Cancer | completed | Phase 2 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 3, 2013 | clinicaltrials |
| NCT01911741 | A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects | completed | Phase 1 | 55 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jul 30, 2013 | clinicaltrials |
| NCT00003517 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00016107 | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00039104 | Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00608920 | Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping(SPECT) | completed | N/A | 15 | Washington University School of MedicineOTHER | 1 | May 24, 2013 | clinicaltrials |
| NCT00182052 | Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer | completed | Phase 3 | 100 | Massachusetts General HospitalOTHER | 1 | May 23, 2013 | clinicaltrials |
| NCT00040755 | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00096499 | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00005039 | Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) | terminated | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00109811 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005067 | Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00512668 | Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT01663415 | A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Sep 17, 2012 | clinicaltrials |
| NCT01487902 | The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer | unknown | Phase 2 | 90 | Asan Medical CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
| NCT01478412 | An Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer(Clarity) | unknown | — | 20 | John Chang, MDOTHER | 1 | Dec 7, 2011 | clinicaltrials |
| NCT00502164 | Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer(AZD2171IL/0003) | completed | Phase 1 | 40 | AstraZenecaINDUSTRY | 1 | Jan 21, 2011 | clinicaltrials |
| NCT00430235 | A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer | completed | Phase 2 | 39 | British Columbia Cancer AgencyOTHER | 1 | Aug 5, 2010 | clinicaltrials |
| NCT00181558 | Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone | completed | Phase 2 | 44 | Massachusetts General HospitalOTHER | 1 | May 10, 2010 | clinicaltrials |
| NCT00140478 | Mifepristone (RU-486) in Androgen Independent Prostate Cancer | completed | Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 9, 2009 | clinicaltrials |
| NCT00379132 | 131-I-TM-601 Study in Adults With Solid Tumors | completed | Phase 1 | 60 | TransMolecularINDUSTRY | 1 | Mar 31, 2009 | clinicaltrials |
| NCT00764166 | A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel(RisingPSA) | unknown | Phase 3 | 254 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 1, 2008 | clinicaltrials |
| NCT00636259 | Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer | no longer available | — | — | AstraZenecaINDUSTRY | 0 | Jun 11, 2008 | clinicaltrials |
| NCT00540059 | Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial | completed | — | 1,950 | AstraZenecaINDUSTRY | 0 | Oct 5, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Dec 5, 2013source: clinicaltrials